SHR-1703

DRUG5 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Atridia Pty Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd

Conditions

AsthmaAsthma With Eosinophilic PhenotypeEosinophilic Granulomatosis With Polyangiitis

Phase 1

A Trial of SHR-1703 in Healthy Adults

CompletedNCT04480762

Jiangsu HengRui Medicine Co., Ltd.Asthma

Start: 2020-08-04End: 2021-09-21Updated: 2022-11-14

A Trial of SHR-1703 in Healthy Subjects

TerminatedNCT04855591

Atridia Pty Ltd.Asthma

Start: 2021-06-14End: 2021-11-18Updated: 2021-12-01

A Trial of SHR-1703 in Asthma

Jiangsu HengRui Medicine Co., Ltd.Asthma

Start: 2021-10-12End: 2023-06-15Updated: 2023-04-25

Phase 2

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

CompletedNCT05522439

Jiangsu HengRui Medicine Co., Ltd.Asthma With Eosinophilic Phenotype

Start: 2022-12-22End: 2024-09-12Updated: 2025-05-28

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

RecruitingNCT05979051

Guangdong Hengrui Pharmaceutical Co., LtdEosinophilic Granulomatosis With Polyangiitis

Start: 2023-11-16End: 2028-12-31Target: 166Updated: 2025-12-04

Related Papers

Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study

Expert Opinion on Investigational Drugs2024-05-284 citations